2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理

2021-03-10 Mayo Clin Proc . 2021 Mar 10

2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内

中文标题：

英文标题：

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement

发布机构：

发布日期：

2021-03-10

简要介绍：

2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内分泌、激素以及泌尿系统用药的术前管理提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=632b71c0020e673d, title=2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理, enTitle=Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement, guiderFrom=Mayo Clin Proc . 2021 Mar 10, authorId=0, author=, summary=2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内, cover=https://img.medsci.cn/2021330/1617116171763_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Mar 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年3月，围术期评估和质量改进学会(SPAQI)发布了内分泌、激素以及泌尿系统用药的术前管理共识声明。围手术期药物管理具有挑战性，术前优化的重要内容是对患者长期使用药物的适当管理。本文主要针对内分泌、激素以及泌尿系统用药的术前管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;"> </div>, tagList=[TagDto(tagId=111064, tagName=术前管理)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=943, guiderKeyword=内分泌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=21987, appHits=125, showAppHits=0, pcHits=705, showPcHits=21862, likes=1, shares=18, comments=16, approvalStatus=1, publishedTime=Tue Mar 30 23:50:47 CST 2021, publishedTimeString=2021-03-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Mar 30 22:57:13 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 09:10:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理.pdf)])

2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理.pdf

下载请点击：

评论区 (13)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
2021-12-16 龙珠

学习好资料

94 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
2021-11-06 ms9000000892709945

学习了

94 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
2021-08-17 ms1000001256854968

好

100 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
2021-06-23 ms2000000895029841

很好

140 0 举报
[GetPortalCommentsPageByObjectIdResponse(id=1080672, encodeId=5a0410806e2ed, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 10:26:49 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1067583, encodeId=1453106e5839e, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=081f5687511, createdName=ms9000000892709945, createdTime=Sat Nov 06 14:40:36 CST 2021, time=2021-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008705, encodeId=cc341008e05cd, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ff25575336, createdName=ms1000001256854968, createdTime=Tue Aug 17 14:32:14 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976176, encodeId=d55b9e617695, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20095471548, createdName=ms2000000895029841, createdTime=Wed Jun 23 12:59:02 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967606, encodeId=07af96e60667, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cfe5505847, createdName=ms9000000564533451, createdTime=Fri May 21 21:11:03 CST 2021, time=2021-05-21, status=1, ipAttribution=)]
2021-05-21 ms9000000564533451

学习了

136 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科指南

2021 SPAQI共识声明：内分泌、激素以及泌尿系统用药的术前管理

拓展阅读

科室

工具

服务